Antonio Valone, DO
Nuclear Cardiology · Moorestown, NJNPI 1336598713
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $745 and has fallen 54.3% since, to $341 in 2025. That places this record below the midpoint for nuclear cardiology clinicians in NJ, where the typical reported total is $3,343.
Across 70 payments — averaging $37.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$469
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$362
- Impulse Dynamics (USA) Inc.$294
- Atricure, Inc.$213
- Boston Scientific$207
- E.r. Squibb & Sons, L.L.C.$144
- plus $943 from 11 others
What the payments were for
- Food & beverage$2,42592%
- Education$2098%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $469 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $362 |
| Impulse Dynamics (USA) Inc. | 4 | $294 |
| Atricure, Inc. | 2 | $213 |
| Boston Scientific | 4 | $207 |
| E.r. Squibb & Sons, L.L.C. | 18 | $144 |
| Novartis | 6 | $144 |
| AstraZeneca | 2 | $130 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Biotronik Inc. | 1 | $111 |
| Pfizer | 1 | $108 |
| Amgen | 6 | $102 |
| Kestra Medical Technology Services, Inc. | 4 | $75 |
| Boehringer Ingelheim | 4 | $59 |
| Johnson & Johnson | 2 | $36 |
| Merck | 2 | $30 |
| Edwards Lifesciences | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$317
- EnSite Precision Cardiac Mapping System$209
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$188
- ENSITE PRECISION$138
- UPTRAVI$125
- OPSUMIT$125
- Confirm Rx$122
- FARXIGA$117
- ELIQUIS$108
- LifeVest$100
How this compares
$2,634 in reported general payments places this provider in the 35th percentile of 34 nuclear cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $175,899 |
| EntrestoSacubitril/Valsartan | 63 | $73,540 |
| XareltoRivaroxaban | 53 | $60,067 |
| Repatha SureclickEvolocumab | 50 | $40,070 |
| Praluent PenAlirocumab | 30 | $22,608 |
| BrilintaTicagrelor | 16 | $11,342 |
| FarxigaDapagliflozin Propanediol | 11 | $6,757 |
| Metoprolol Succinate | 277 | $3,704 |
| Rosuvastatin Calcium | 128 | $1,972 |
| Atorvastatin Calcium | 263 | $1,921 |
| Ezetimibe | 83 | $1,611 |
| Valsartan | 46 | $1,465 |
| Losartan Potassium | 157 | $1,277 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 22 | $910 |
| Carvedilol | 60 | $882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $108 | $175,899150 claims |
| NovartisEntresto | $144 | $73,54063 claims |
| Johnson & JohnsonXarelto | $36 | $60,06753 claims |
| AstraZenecaBrilinta, Farxiga | $130 | $18,09827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 34 nuclear cardiology providers in New Jersey.
Other nuclear cardiology in Moorestown
- Ralph RussoMoorestown$11K
- Anthony SauerweinMoorestown$10K
- Samuel VentrellaMoorestown$7K
- Thomas GalskiMoorestown$6K
- Jay SussmanMoorestown$3K
- Pamela FazioMoorestown$2K
- Brett SealoveEatontown$410K
- Madhav UpadhyayaTinton Falls$89K
- Mark FinchCherry Hill$28K
- Hafeza ShaikhWillingboro$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.